[144] Kiniksa Pharmaceuticals International, plc SEC Filing

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 16,200 Class A ordinary shares through Charles Schwab, with an aggregate market value of $547,070, slated for 08/18/2025 on NASDAQ. The filing documents the acquisition history for those shares, including founders' shares from 09/16/2015, two performance award lapses in 03/2022 and 03/2023, and an 08/18/2025 cashless option exercise. The filer, identified by past sales as Eben Tessari at a Lexington, MA address, sold 257,681 shares across seven transactions in May–August 2025, generating total gross proceeds of $8,111,307. The notice includes the seller's representation about lack of undisclosed material adverse information.

Positive

• Required disclosure provided: The Form 144 supplies acquisition history and sale details as required under Rule 144
• Substantial liquidity demonstrated: Prior sales generated $8,111,307 in gross proceeds, indicating marketability of the shares

Negative

• Large insider dispositions: 257,681 shares sold May–Aug 2025, which may be perceived negatively by investors
• Concentrated recent selling: Multiple sales by the same person in a short period could signal heightened insider selling pressure

Insights

Financial Analyst

TL;DR: Recent and proposed insider sales are sizeable in aggregate but the filing is a routine Rule 144 disclosure.

The Form 144 shows a proposed sale of 16,200 Class A shares valued at $547,070 and documents prior acquisitions by the filer including founders shares, performance award lapses, and a recent cashless option exercise. The filer completed seven sales between 05/19/2025 and 08/05/2025 totaling 257,681 shares for $8,111,307 in gross proceeds. From a financial viewpoint, these are material-sized insider dispositions in absolute dollars but the filing itself is procedural and does not provide operational or earnings information.

Corporate Governance Expert

TL;DR: Concentrated insider selling is notable and raises governance/market-signal questions but the form discloses no misconduct.

The disclosure documents repeated sales by the same individual (Eben Tessari) over a short period and a further proposed sale. Such clustered insider sales can be significant for shareholder perception and may warrant investor attention to executive shareholding trends and any announced plans. The filing contains the required representation that the seller is unaware of undisclosed material adverse information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	16200	547070.00	43472928	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	09/16/2015	Founders Shares	Kiniksa Pharmaceuticals International, plc			7000	09/16/2015	NA
Class A Ordinary Shares	03/20/2022	Performance Award Lapse	Kiniksa Pharmaceuticals International, plc			1143	03/20/2022	Equity Compensation
Class A Ordinary Shares	03/20/2023	Performance Award Lapse	Kiniksa Pharmaceuticals International, plc			1557	03/20/2023	Equity Compensation
Class A Ordinary Shares	08/18/2025	Employee Stock Option Exercise	Kiniksa Pharmaceuticals International, plc			6500	08/18/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	05/19/2025	12000	316898.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/09/2025	10319	313453.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/10/2025	15506	472239.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/11/2025	45042	1374277.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	06/16/2025	17300	489171.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	07/14/2025	18900	542860.00
Eben Tessari 100 Hayden Avenue Lexington MA 02421	Kiniksa Pharmaceuticals International, plc	08/05/2025	138614	4602409.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the KNSA Form 144 filed on behalf of Eben Tessari report?

The notice proposes sale of 16,200 Class A ordinary shares valued at $547,070 with acquisition history and a plan to sell on 08/18/2025 via Charles Schwab.

How many KNSA shares did the filer sell in the past three months and for how much?

The filer sold a total of 257,681 shares across seven transactions between 05/19/2025 and 08/05/2025, generating $8,111,307 in gross proceeds.

What types of acquisitions produced the shares proposed for sale?

Shares were acquired as founders shares (09/16/2015), through performance award lapses (03/20/2022 and 03/20/2023), and via an employee option exercise (08/18/2025).

On which exchange and through which broker will the proposed sale occur?

The proposed sale is listed for NASDAQ via broker Charles Schwab & Co., Inc.

Does the filing state whether the seller knows of any undisclosed material information?

Yes; the filer signs a representation that he does not know any material adverse information regarding the issuer that has not been publicly disclosed.

Are the sale proceeds or price per share disclosed for the proposed 16,200-share sale?

The aggregate market value for the proposed sale is provided as $547,070; the filing does not state an explicit per-share price.